


THERAPY DECISION TREE FOR CANINE ATOPIC DERMATITIS

Sponsored by Virbac

This tree was created with the help and expertise of Dr. William Oldenhoff, DVM, DACVD, and Dr. Shannon Palermo, VMD, DACVIM.



IMPORTANT SAFETY INFORMATION

GENESIS® Topical Spray (0.015% triamcinolone acetate): For use on dogs only. Wear gloves when applying the product. The use of this product on dogs less than eight pounds, less than one year of age, breeding, pregnant, or lactating has not been evaluated. Adverse events of polyuria and polyphagia have been reported in <6% of dogs receiving treatment. For full prescribing information, contact Virbac at 1-800-338-3659 or visit us.virbac.com.

CHRONIC CONTROL OF CANINE ATOPIC DERMATITIS

Confirm any inciting flare factors have been avoided or removed

- ▶ Diet trial if clinical signs are nonseasonal and presentation is consistent with possible adverse food reaction
- ▶ Effective year-round flea and tick prevention
- ▶ Secondary bacterial/fungal infections and any concurrent conditions (eg, endocrine disease) appropriately treated

Atopic dermatitis is a multifactorial disease process, requiring a multimodal treatment approach to achieve optimal results


- ▶ Breaking the cycle of inflammation will decrease not only pruritus but potentially otitis, secondary infections, and other clinical signs
- ▶ Use of topical therapies to treat occasional flare-ups and long-term use of systemic therapies may be required for treatment success²
- ▶ Consider immunotherapy to address the underlying cause of atopic dermatitis (eg, hypersensitivity)

Evaluate patient's individual needs and client's budget and compliance to select appropriate long-term therapy

See Proactive Therapy, next page

Immunotherapy

- ▶ Sole treatment for environmental-induced atopic dermatitis that has the potential to eliminate need for other therapies
- ▶ Available in both subcutaneous and sublingual forms
- ▶ In a study, within 12 months, ≈50% of dogs had improved clinical signs, and 80% had a decrease in need for anti-inflammatory/antipruritic medications⁵



IMPORTANT SAFETY INFORMATION

CYCLAVANCE™ (cyclosporine oral solution)(USP Modified): For use in dogs only. Wear gloves during and wash hands after administration. Gastrointestinal problems and gingival hyperplasia may occur at the initial recommended dose of CYCLAVANCE Oral Solution for Dogs. CYCLAVANCE Oral Solution for Dogs should be used with caution: 1) in cases with diabetes mellitus as it may cause elevated levels of serum glucose; 2) in dogs with renal insufficiency since the effect of cyclosporine use on dogs with compromised renal function has not been studied; 3) in simultaneous administration with drugs that suppress the P-450 enzyme system, such as azoles (e.g. ketoconazole), that may lead to increased plasma levels of cyclosporine. Killed vaccines are recommended for dogs receiving CYCLAVANCE Oral Solution for Dogs because the impact of cyclosporine on the immune response to modified live vaccines has not been evaluated. For full prescribing information, contact Virbac at 1-800-338-3659 or visit us.virbac.com.

References

1. DeBoer DJ, Schafer JH, Salsbury CS, et al. Multiple-center study of reduced-concentration triamcinolone topical solution for the treatment of dogs with known or suspected allergic pruritus. *Am J Vet Res.* 2002;63(3):408-413.
2. Olivry T, DeBoer DJ, Favrot C, et al. Treatment of canine atopic dermatitis: 2015 updated guidelines from the International Committee on Allergic Diseases of Animals (ICADA). *BMC Vet Res.* 2015;11:210.
3. Cosgrove SB, Wren JA, Cleaver DM, et al. Efficacy and safety of oclacitinib for the control of pruritus and associated skin lesions in dogs with canine allergic dermatitis. *Vet Dermatol.* 2013;24(5):479–e114.
4. Steffan J, Parks C, Seewald W, North American Veterinary Dermatology Cyclosporine Study Group. Clinical trial evaluating the efficacy and safety of cyclosporine in dogs with atopic dermatitis. *J Am Vet Med Assoc.* 2005;226(11):1855–1863.
5. Olivry T, DeBoer DJ, Favrot C, et al. Treatment of canine atopic dermatitis: 2010 clinical practice guidelines from the International Task Force on Canine Atopic Dermatitis. *Vet Dermatol.* 2010;21(3):233–248.
6. Steffan J, Favrot C, Mueller R. A systematic review and meta-analysis of the efficacy and safety of cyclosporin for the treatment of atopic dermatitis in dogs. *Vet Dermatol.* 2006;17(1):3–16.
7. Forsythe P, Paterson S. Cyclosporin 10 years on: indications and efficacy. *Vet Rec.* 2014;174(Suppl 2):13-21.
8. Navarro C, Crastes N, Benizeau E, McGahie D. Voluntary acceptance and consumption of two oral cyclosporin formulations in dogs: two randomised, controlled studies. *Ir Vet J.* 2015;68(1):3.
9. Löflath A, von Voigts-Rhetz A, Jaeger K, Schmid M, Kuechenhoff H, Mueller RS. The efficacy of a commercial shampoo and whirlpooling in the treatment of canine pruritus - a double-blinded, randomized, placebo-controlled study. *Vet Dermatol.* 2007;18(6):427-431.